{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:15:20Z","timestamp":1756192520815},"reference-count":18,"publisher":"Wiley","issue":"1-2","license":[{"start":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T00:00:00Z","timestamp":1258934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Paediatrics Child Health"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p><jats:bold>Aim:\u2003<\/jats:bold> Parenteral phenobarbitone was unavailable in South Africa from 2005 to 2006. This study aimed to establish the effectiveness of enteral phenobarbitone in the management of childhood status epilepticus.<\/jats:p><jats:p><jats:bold>Method:\u2003<\/jats:bold> Patients in status epilepticus (December 2005\u2013June 2006) received 20\u2003mg\/kg phenobarbitone via nasogastric tube in addition to standard status interventions (benzodiazepine boluses, phenytoin infusion). Phenobarbitone concentrations were taken post loading. Phenobarbitone population pharmacokinetics was analysed using non\u2010linear mixed effects modelling.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Sixteen patients (7 female, 9 male) were assessed, median age 5\u2003months (range 9\u2003days\u2013168\u2003months). Nine patients received 20\u2003mg\/kg; the maximum total dosage administered was 80\u2003mg\/kg with a concentration of 283\u2003\u00b5mol\/L. The typical population value of the volume of distribution was 1.2 (95% confidence interval (CI): 0.8\u20131.6)\u2003L\/kg with interindividual variability (as coefficient of variation) of 53% (95% CI, 9\u201374%). Seizure control was documented within 1\u2003h (<jats:italic>n<\/jats:italic>= 8), 1<jats:sup>1<\/jats:sup>\/<jats:sub>2<\/jats:sub>\u2003h (<jats:italic>n<\/jats:italic>= 1), 3\u2003h (<jats:italic>n<\/jats:italic>= 1) and 4\u2003h (<jats:italic>n<\/jats:italic>= 5) following enteral phenobarbitone loading. No adverse effects were apparent from the enteral phenobarbitone administration.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> Patients tolerated enteral loading with phenobarbitone. A single enteral loading dose resulted in adequate phenobarbitone exposure. This practice was a safe intervention for centres lacking parenteral phenobarbitone. Therapeutic concentrations and seizure control after enteral loading suggested a role for enteral phenobarbitone in the management of acute status epilepticus as well as prophylaxis against seizure recurrence.<\/jats:p>","DOI":"10.1111\/j.1440-1754.2009.01611.x","type":"journal-article","created":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T10:54:16Z","timestamp":1258973656000},"page":"17-22","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rescue therapy with high\u2010dose oral phenobarbitone loading for refractory status epilepticus"],"prefix":"10.1111","volume":"46","author":[{"given":"Jo M","family":"Wilmshurst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan\u2010Stefan","family":"Van Der Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Blockman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,27]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2005.tb01124.x"},{"key":"e_1_2_9_3_2","first-page":"712","article-title":"Status epilepticus \u2013 a plea for phenobarbitone","volume":"95","author":"Wallis LA","year":"2005","journal-title":"SAMJ"},{"key":"e_1_2_9_4_2","first-page":"422","article-title":"Withdrawal of parenteral phenobarbitone\u2010implications for resource\u2010poor countries","volume":"95","author":"Wilmshurst JM","year":"2005","journal-title":"SAMJ"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.7.1035"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.06.014"},{"key":"e_1_2_9_7_2","first-page":"64","volume-title":"Handbook of Paediatrics for Developing Countries","author":"Wilmshurst JM","year":"2004"},{"key":"e_1_2_9_8_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000457110","article-title":"Pharmacokinetics of phenobarbitone in protein energy malnutrition","volume":"9","author":"Syed GB","year":"1986","journal-title":"Dev. Pharmacol. Ther"},{"key":"e_1_2_9_9_2","first-page":"139","volume-title":"In: Advanced Paediatric Life Support. The Practical Approach","author":"Mackway\u2010Jones K","year":"2005"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03971.x"},{"key":"e_1_2_9_11_2","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland M","year":"1994"},{"key":"e_1_2_9_12_2","volume-title":"NONMEM Users' Guides","author":"Beal SL","year":"1996"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194954"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2005.00619.x"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_9_17_2","unstructured":"Committee for Medicinal Products for Human Use.Guideline on Reporting. The Results of Population Pharmacokinetic Analyses. CHMP\/EWP\/185990\/06 2007."},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(01)00365-4"},{"key":"e_1_2_9_19_2","first-page":"23","article-title":"Non\u2010intravenous high\u2010dose phenobarbital therapy for status epilepticus refractory to continuous infusion of midazolam or pentobarbital: report of three cases","volume":"34","author":"Sudoh A","year":"2002","journal-title":"No To Hattatsu"}],"container-title":["Journal of Paediatrics and Child Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1754.2009.01611.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1754.2009.01611.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T15:38:53Z","timestamp":1693409933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1754.2009.01611.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":18,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1440-1754.2009.01611.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1754.2009.01611.x","archive":["Portico"],"relation":{},"ISSN":["1034-4810","1440-1754"],"issn-type":[{"value":"1034-4810","type":"print"},{"value":"1440-1754","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"2010-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}